Abstract: Ｏｂｊｅｃｔｉｖｅ：To study the application of antiphosphatidylserine／prothrombin antibodies (aPS／PT) and “standard” antiphospholipid antibodies(aPL) in lupus nephritis(LN).
Ｍｅｔｈｏｄｏｌｏｇｙ：82 LN patients treated in Jinling Hospital from December 2020 to April 2021 were selected to detect lupus anticoagulant (LA), anticardiolipin antibodies (aCL), antiβ2glycoprotein1 antibodies (aβ2GP1) and aPS／PT.According to the criteria aPL results, the patients were divided into “standard” positive group and “standard” negative group,and than divided into “standard” and／or aPS／PT positive group and “standard” and aPS／PT negative group according to the results of aPS／PT.The clinical and laboratory data and renal histopathology of each group were compared.
Ｒｅｓｕｌｔｓ：The positive rates of LA, aCL and aβ2GP1 in 82 LN patients were 220％, 134％ and 390％, respectively.A total of 40 (488％) LN patients were positive in IgG／IgM aPS／PT, including 256％ patients positive in aPS／PT IgG and 354％ positive in aPS／PT IgM.Among the LA positive patients, 944％ of the patients were IgG／IgM aPS／PT positive.The consistency between aPS／PT IgG and LA was the strongest, and the Cohens kappa coefficient was 0429 (P<001).IgG aPS／PT positive was positively correlated with the risk of thrombosis and neuropsychiatric lupus.The levels of C3 and C4 in the “standard” and／or aPS／PT positive group were significantly lower than those in the negative group, while the level of SLEDAI in the “standard” and／or aPS／PT positive group was significantly higher than that in the “standard” and aPS／PT negative group.
Ｃｏｎｃｌｕｓｉｏｎ：There is a good correlation and consistency between aPS／PT and LA.Additional detection of aPS／PT is helpful to identify the risk of thrombotic events, neuropsychiatric lupus and lupus activity in patients with LN.